Tirzepatide linked to slower growth in older adults’ care costs
At 12–18 months, monthly costs excluding tirzepatide changed $319 less per person among persistent users than among matched nonusers.
Stake: Eli Lilly and Company, which develops tirzepatide, funded the study; authors work for it, hold shares in it and take fees from it.
Edited by Boris Djordjevic · AgingResearch.News
US adults older than 55 with obesity, or overweight plus a weight-related condition, and no diabetes were studied in a retrospective observational analysis. Researchers compared 15,843 tirzepatide users with 15,843 matched people using neither tirzepatide nor related drugs. Women made up 68.8% of users and 67.8% of controls.
Researchers tracked costs for up to 18 months, comparing changes against the preceding year. Costs excluding tirzepatide stayed largely unchanged among users but rose among controls. The difference in changes favored users by $145 per person per month at 6–12 months and $319 at 12–18 months, in 2025 dollars. An analysis that ended follow-up for both members of each matched pair when either stopped qualifying estimated a $607 monthly difference at 12–18 months. Follow-up ended when users stopped tirzepatide.
Why it matters
For older adults with obesity or overweight, the study addressed whether lower spending elsewhere might offset weight-management drug costs. The authors suggested tirzepatide may generate near-term savings for older people who stay on treatment.
Caveats
This observational study cannot establish that tirzepatide caused the cost differences, and excluding its price means these figures do not establish total savings. Only 793 people per group remained in the paired analysis at 12–18 months; the findings concern continued users without diabetes.
The paper
Eli Lilly (United States)
Diabetes, Obesity & Metabolism, Aug 24, 2026, Open access
